Firefly Neuroscience Cuts Authorized Shares by 98% While Expanding Incentive Plan by 2 Million

summarizeSummary

Firefly Neuroscience's annual meeting delivered a 98% reduction in authorized shares, limiting future dilution, but also added 2 million shares to its incentive plan, increasing potential equity award dilution by about 12.8%.

check_boxKey Events · Corporate Governance and Compliance · AIFF

• Authorized Shares Slashed 98%

  A charter amendment reducing authorized shares from 5,001,000,000 to 101,000,000 (100M common, 1M preferred) was approved by stockholders, effective August 5, 2026.

• Incentive Plan Expanded by 2M Shares

  The share limit under the 2024 Long-Term Incentive Plan was increased by 2,000,000 shares to 3,707,496, representing potential dilution of about 12.8% of the 15.6M shares outstanding.

• Director Elected, Auditor Ratified

  Arun Menawat was elected as a Class III director, and CBIZ Canada, LLP was ratified as the independent auditor for fiscal year 2026.

• Say-on-Pay Approved

  A non-binding advisory vote approved executive compensation with 4,331,361 votes for, 76,601 against, and 23,017 abstentions.

auto_awesomeAnalysis · AIFF · Technology

At its annual meeting, Firefly Neuroscience secured stockholder approval for two moves that send a mixed message on dilution. A charter amendment slashes authorized shares from 5 billion to 101 million, sharply limiting the company's ability to issue massive dilutive equity in the future. At the same time, the 2024 Long-Term Incentive Plan was expanded by 2 million shares, raising the plan limit to 3,707,496 and introducing potential dilution of about 12.8% if all new shares are granted. With the company still under a going-concern warning, these governance changes are critical for understanding how management can fund operations and incentivize talent.